Good MorningEquity markets remained relatively steady on Wednesday, following the release of the CPI report and news of progress in trade negotiations. The CPI was cooler than expected, alleviating some but not all fears that tariffs would accelerate inflation. The risk is that the tariff impact isn't fully priced into the economy, and subsequent data will reflect it. The takeaway is that the FOMC is no closer to cutting rates than before the release, although the White House is sure to press for it.
Regarding the trade negotiations, the news is that a framework for a deal has been made and is to be approved by Trump and Xi. The caveat is that a framework isn't a deal, and there is still a long way to go before the endgame. Until then, Commerce Secretary Lutnick says there will be no further changes to tariffs on China, providing some stability to the outlook. Featured: While America watches the polls, watch this AI IPO (Ad) 
|
Materials | | Conventional investor wisdom holds that the consumer discretionary sector performs best when the economy is thriving and customers have money to spend. Low interest rates and strong job growth may be other important indicators of a potential boom in consumer discretionary companies.
With those thin... Read the Full Story |
|
From Our Partners | | Weiss Ratings rated Nvidia a Buy back in 2011, long before the AI boom. Since then, Nvidia has climbed nearly 30,000%.
This year alone, the same ratings system has identified 252 new Buy-rated stocks, including AI picks already up 37%, 55%, and 264%.
Now it's flagging a fresh group of stocks tied to the next AI boom. | | See the top AI stocks our ratings system is flagging now |
|
Communication Services | |
In mid-June 2025, space-based cellular broadband provider AST SpaceMobile Inc. (NASDAQ: ASTS) reached its highest share price in nearly 10 months, with analysts viewing the stock optimistically and calling for nearly 19% further upside potential.
But a five-day return of more than 38% could sca... Read the Full Story |
|
Consumer Discretionary | |
Parents beware. Christmas came early in 2025 as Nintendo Co., Ltd. (OTCMKTS: NTDOY) released its hotly anticipated Switch 2 handheld gaming console. It comes with a hefty price tag of $449.00.
However, investors who bought NTDOY stock earlier this year may easily have enough profits to cover th... Read the Full Story |
|
From Our Partners | | A close associate of Elon Musk is raising eyebrows with a bold claim about what he may do next in artificial intelligence.
Industry watchers point to an emerging AI segment positioned for significant growth in the years ahead, according to research shared by James Altucher. | | Click here to see the full details on this emerging AI opportunity |
|
Technology | |
There was absolutely nothing wrong with GitLab’s (NASDAQ: GTLB) Q1 earnings report and guidance. Nothing that is, except a wee bit of tepidness relative to analysts' relatively high bar. The sticking point, the cause for the 12% post-release price plunge, is that the guidance for Q2 revenu... Read the Full Story |
|
Consumer Discretionary | |
Dave & Buster's (NASDAQ: PLAY) FQ1 results and outlook for the year affirm that its CEO change and Back-to-Basics strategy were the right move. The critical detail is that this heavily shorted market is amid a short-covering rally and rebound that will result in a complete price reversal and... Read the Full Story |
|
From Our Partners | | Ian Cooper breaks down a simple, repeatable options setup designed to replace guesswork with clarity and confidence.
No complicated indicators or constant market watching required, just a repeatable approach built for everyday traders.
His free report walks through step-by-step trade blueprints, the number one mistake rookie traders make, and how to filter out market noise. | | Get the free report and see the simple options setup today. |
|
Consumer Discretionary | |
After mostly recovering from a brutal multi-month selloff through April, shares of Amazon.com Inc. (NASDAQ: AMZN) now find themselves at one of those make-or-break moments that could define the next few months of price action. The stock closed on Tuesday at just over $217, putting it within a co... Read the Full Story |
|
Industrials | |
Rocket Lab USA (NASDAQ: RKLB) has long been a standout among space-focused stocks within the aerospace and defense sector. Over the past year, RKLB shares have soared more than 500%, fueled by renewed investor interest in space innovation and national defense contracts. Most recently, the stock ... Read the Full Story |
|
Consumer Discretionary | |
When a stock climbs 14% in just two trading sessions despite getting hit with not one but two analyst downgrades, the market is sending a clear message. Tesla Inc (NASDAQ: TSLA) has done exactly that this week, shrugging off downgrades from both Baird and Argus Research as if they were minor spe... Read the Full Story |
|
Markets | |
Remarkably, the market is edging closer to record territory, following an impressive V-shaped reversal off its 52-week lows. Many investors may be seeking ways to gain exposure, particularly with the potential for a pullback and consolidation before another leg higher.
Since bottoming out, the SP... Read the Full Story |
|
Communication Services | |
Recent volatility in Warner Bros. Discovery (NASDAQ: WBD) stock is tied directly to a landmark strategic pivot. Since its formation in April 2022, the entertainment sector giant has traded at what many analysts have called a conglomerate discount, where the combined company's stock is valued for... Read the Full Story |
|
Thursday's Early Bird Stock Of The Day EyePoint Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery. Its lead product candidate is EYP-1901, an investigational sustained delivery treatment for VEGF-mediated retinal diseases combining vorolanib, a selective and patent-protected tyrosine kinase inhibitor with Durasert E which is in Phase 2 clinical trials for wet age-related macular degeneration (wet AMD), non-proliferative diabetic retinopathy (NPDR), and diabetic macular edema (DME). The company's pipeline programs also include EYP-2301, a promising TIE-2 agonist formulated in Durasert E to potentially improve outcomes in serious retinal diseases. The company was formerly known as pSivida Corp. and changed its name to EyePoint Pharmaceuticals, Inc. in March 2018. EyePoint Pharmaceuticals, Inc. was incorporated in 1987 and is headquartered in Watertown, Massachusetts. | | View Today's Stock Pick |
|
